These findings warrant further investigation into the mechanistic roles of THBS1 and LTF in MM progression, their utility in clinical decision-making algorithms, potential therapeutic applications targeting these pathways, and providing a foundation for developing minimally invasive, protein-based monitoring strategies to improve clinical management of MM patients. This evidence concerns the gene THBS1 and Miyoshi myopathy.